Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Routine human immunodeficiency virus testing: an economic evaluation of current guidelines.

Rochelle P Walensky1, Milton C Weinstein, April D Kimmel

  • 1Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, and the Partners AIDS Research Center, Harvard Medical School, Boston, Massachusetts 02114, USA. rwalensky@partners.org

The American Journal of Medicine
|March 5, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How Big Is the "Gray Area"? Navigating Health-Threatening Previability Pregnancy Complications in States With Abortion Restrictions.

Annals of internal medicine·2026
Same author

Cost-Effectiveness of Community Tuberculosis Screening in South Africa.

American journal of respiratory and critical care medicine·2026
Same author

HIV disease progression following WHO treat all guideline adoption among people enrolled in HIV care in Central Africa: A multistate analysis.

Annals of epidemiology·2026
Same author

Component Clinical and Cost Outcomes Complementing Value of Information: Case Study of a Tuberculosis Diagnostics Clinical Trial.

PharmacoEconomics·2026
Same author

Potential long-acting tuberculosis treatment for people with HIV: cost-effectiveness benchmarks.

Annals of the American Thoracic Society·2026
Same author

Sustaining Rwanda's HIV response after elimination of PEPFAR funding: a modelling analysis of HIV epidemic and care continuum outcomes.

Journal of the International AIDS Society·2026
Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026
Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026
Same journal

Cave Canem - Beware of the Dog.

The American journal of medicine·2026
Same journal

Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

The American journal of medicine·2026
Same journal

Mesenteric Panniculitis.

The American journal of medicine·2026
Same journal

Hypercalcemia and hyperferritinemia in a patient with Graves' disease disease.

The American journal of medicine·2026
See all related articles

Routine HIV screening in hospitals is cost-effective, even at lower prevalence rates. Implementing current guidelines can link infected patients to life-sustaining care, improving health outcomes.

Area of Science:

  • Public Health
  • Health Economics
  • Infectious Disease Epidemiology

Background:

  • Current CDC guidelines recommend HIV screening for hospital patients with >=1% prevalence.
  • This 1% threshold has not been re-evaluated since HIV became effectively treatable in 1995.
  • The study aims to assess the clinical and economic impact of current and alternative HIV screening thresholds.

Purpose of the Study:

  • To evaluate the cost-effectiveness of current HIV screening guidelines.
  • To analyze the impact of alternative HIV prevalence thresholds for screening.
  • To determine the clinical effectiveness of expanded HIV screening programs.

Main Methods:

  • A cost-effectiveness analysis was conducted.
  • A computer simulation model of HIV screening and disease in US hospital inpatients was utilized.

Related Experiment Videos

Main Results:

  • HIV screening at 1% prevalence increased life expectancy by 6.13 years per 1000 inpatients at $35,400/QALY.
  • Screening at 0.1% prevalence yielded a ratio of $64,500/QALY.
  • Increased testing costs to $103 still resulted in a cost-effectiveness ratio below $100,000/QALY at 0.1% prevalence.

Conclusions:

  • Routine inpatient HIV screening is cost-effective and remains so at 10x lower prevalence.
  • Current HIV counseling, testing, and referral guidelines should be implemented nationwide.
  • These programs effectively link infected patients to essential, life-sustaining care.